{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:13:51Z","timestamp":1787620431315,"version":"build-2736575974"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02883-3","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:36:25Z","timestamp":1776231385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A conceptual blueprint for \u201cturning cold to hot\u201d in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects"],"prefix":"10.1186","volume":"24","author":[{"given":"Bai","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"Suppl 7","key":"2883_CR1","doi-asserted-by":"publisher","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320\u20135.","journal-title":"Ann Oncol"},{"issue":"1","key":"2883_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23(1):192.","journal-title":"Mol Cancer"},{"issue":"22","key":"2883_CR3","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385(22):2066\u201376.","journal-title":"N Engl J Med"},{"key":"2883_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","volume":"500","author":"C Chen","year":"2021","unstructured":"Chen C, et al. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1\u201310.","journal-title":"Cancer Lett"},{"issue":"1","key":"2883_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, et al. Osteosarcoma. Nat Rev Dis Primers. 2022;8(1):77.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2883_CR6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.stem.2024.08.010","volume":"31","author":"A Al Shihabi","year":"2024","unstructured":"Al Shihabi A, et al. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024;31(10):1524\u2013e15424.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2883_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2012.09.003","volume":"137","author":"J Gill","year":"2013","unstructured":"Gill J, et al. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89\u201399.","journal-title":"Pharmacol Ther"},{"key":"2883_CR8","unstructured":"Board PDQPTE. Osteosarcoma Treatment (PDQ\u00ae): Patient Version, in PDQ Cancer Information Summaries. 2002, National Cancer Institute (US): Bethesda (MD)."},{"issue":"4","key":"2883_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, et al. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021;11(4):838\u201357.","journal-title":"Cancer Discov"},{"issue":"6382","key":"2883_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"11","key":"2883_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2883_CR12","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","volume":"28","author":"KL Davis","year":"2022","unstructured":"Davis KL, et al. A Phase I\/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed\/Refractory Solid Tumors: A Children\u2019s Oncology Group Study ADVL1412. Clin Cancer Res. 2022;28(23):5088\u201397.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2883_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1042\/ETLS20170073","volume":"1","author":"BL Horton","year":"2017","unstructured":"Horton BL, Spranger S. The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. Emerg Top Life Sci. 2017;1(5):447\u201356.","journal-title":"Emerg Top Life Sci"},{"key":"2883_CR14","doi-asserted-by":"publisher","first-page":"1579822","DOI":"10.3389\/fimmu.2025.1579822","volume":"16","author":"Z Han","year":"2025","unstructured":"Han Z, Chen G, Wang D. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies. Front Immunol. 2025;16:1579822.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","volume":"11","author":"H Tian","year":"2023","unstructured":"Tian H, et al. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. Bone Res. 2023;11(1):11.","journal-title":"Bone Res"},{"key":"2883_CR16","doi-asserted-by":"publisher","first-page":"907550","DOI":"10.3389\/fimmu.2022.907550","volume":"13","author":"T Zhu","year":"2022","unstructured":"Zhu T, et al. Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications. Front Immunol. 2022;13:907550.","journal-title":"Front Immunol"},{"key":"2883_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/ITT.S485672","volume":"14","author":"CJ Sholevar","year":"2025","unstructured":"Sholevar CJ, et al. Myeloid Cells in the Immunosuppressive Microenvironment as Immunotargets in Osteosarcoma. Immunotargets Ther. 2025;14:247\u201358.","journal-title":"Immunotargets Ther"},{"issue":"21","key":"2883_CR18","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1158\/1078-0432.CCR-18-4032","volume":"25","author":"Y Suehara","year":"2019","unstructured":"Suehara Y, et al. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clin Cancer Res. 2019;25(21):6346\u201356.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2883_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"CC Wu","year":"2020","unstructured":"Wu CC, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008.","journal-title":"Nat Commun"},{"issue":"3","key":"2883_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/path.5319","volume":"249","author":"GL Negri","year":"2019","unstructured":"Negri GL, et al. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. J Pathol. 2019;249(3):319\u201331.","journal-title":"J Pathol"},{"issue":"12","key":"2883_CR21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","volume":"97","author":"T Tsukahara","year":"2006","unstructured":"Tsukahara T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374\u201380.","journal-title":"Cancer Sci"},{"key":"2883_CR22","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-020-01685-w","volume":"39","author":"J Cui","year":"2020","unstructured":"Cui J, et al. The role of extracelluar matrix in osteosarcoma progression and metastasis. J Exp Clin Cancer Res. 2020;39(1):178.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2883_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/path.4740","volume":"239","author":"C Zandueta","year":"2016","unstructured":"Zandueta C, et al. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis. J Pathol. 2016;239(4):438\u201349.","journal-title":"J Pathol"},{"issue":"7886","key":"2883_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun X, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599(7886):673\u20138.","journal-title":"Nature"},{"key":"2883_CR26","doi-asserted-by":"publisher","first-page":"824117","DOI":"10.3389\/fimmu.2022.824117","volume":"13","author":"B Li","year":"2022","unstructured":"Li B, et al. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis. Front Immunol. 2022;13:824117.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-022-00877-4","volume":"7","author":"DL Wagner","year":"2022","unstructured":"Wagner DL, Klotzsch E. Barring the gates to the battleground: DDR1 promotes immune exclusion in solid tumors. Signal Transduct Target Ther. 2022;7(1):17.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2883_CR28","doi-asserted-by":"publisher","first-page":"103975","DOI":"10.1016\/j.drudis.2024.103975","volume":"29","author":"D Wu","year":"2024","unstructured":"Wu D, et al. DDR1-targeted therapies: current limitations and future potential. Drug Discov Today. 2024;29(5):103975.","journal-title":"Drug Discov Today"},{"issue":"1","key":"2883_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2883_CR30","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11(1):4011.","journal-title":"Nat Commun"},{"issue":"12","key":"2883_CR31","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1158\/0008-5472.CAN-24-3723","volume":"85","author":"J Eigenbrood","year":"2025","unstructured":"Eigenbrood J, et al. Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases. Cancer Res. 2025;85(12):2320\u201337.","journal-title":"Cancer Res"},{"key":"2883_CR32","doi-asserted-by":"crossref","unstructured":"Eigenbrood J et al. Spatial profiling identifies regionally distinct microenvironments and targetable immunosuppressive mechanisms in pediatric osteosarcoma pulmonary metastases. Cancer Res. 2025;85(12):2320\u20132337.","DOI":"10.1158\/0008-5472.CAN-24-3723"},{"issue":"1","key":"2883_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-024-03319-w","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma. BMC Med. 2024;22(1):200.","journal-title":"BMC Med"},{"issue":"13","key":"2883_CR34","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.7150\/thno.73714","volume":"12","author":"X Huang","year":"2022","unstructured":"Huang X, et al. Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma. Theranostics. 2022;12(13):5877\u201387.","journal-title":"Theranostics"},{"key":"2883_CR35","doi-asserted-by":"publisher","first-page":"1445555","DOI":"10.3389\/fimmu.2024.1445555","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, et al. Single-cell RNA sequencing reveals the communications between tumor microenvironment components and tumor metastasis in osteosarcoma. Front Immunol. 2024;15:1445555.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR36","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun. 2022;13(1):7207.","journal-title":"Nat Commun"},{"issue":"2","key":"2883_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10555-025-10257-3","volume":"44","author":"A Dutour","year":"2025","unstructured":"Dutour A, et al. Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy. Cancer Metastasis Rev. 2025;44(2):44.","journal-title":"Cancer Metastasis Rev"},{"key":"2883_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","volume":"1036","author":"TF Gajewski","year":"2017","unstructured":"Gajewski TF, et al. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017;1036:19\u201331.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"2883_CR39","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, et al. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205.","journal-title":"Immunity"},{"issue":"5","key":"2883_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"1","key":"2883_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-025-00691-y","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. Targeting collagen to optimize cancer immunotherapy. Exp Hematol Oncol. 2025;14(1):101.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2883_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-023-01501-9","volume":"8","author":"X Di","year":"2023","unstructured":"Di X, et al. Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets. Signal Transduct Target Ther. 2023;8(1):282.","journal-title":"Signal Transduct Target Ther"},{"key":"2883_CR43","doi-asserted-by":"crossref","unstructured":"Nicolas-Boluda A et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife. 2021;10:e58688.","DOI":"10.7554\/eLife.58688"},{"issue":"1","key":"2883_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12967-022-03768-y","volume":"20","author":"B Deng","year":"2022","unstructured":"Deng B, et al. Biological role of matrix stiffness in tumor growth and treatment. J Transl Med. 2022;20(1):540.","journal-title":"J Transl Med"},{"issue":"1","key":"2883_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34.","journal-title":"J Hematol Oncol"},{"key":"2883_CR46","doi-asserted-by":"publisher","first-page":"1340634","DOI":"10.3389\/fimmu.2023.1340634","volume":"14","author":"W Du","year":"2023","unstructured":"Du W, et al. Extracellular matrix remodeling in the tumor immunity. Front Immunol. 2023;14:1340634.","journal-title":"Front Immunol"},{"issue":"3","key":"2883_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/CS20201474","volume":"136","author":"R Cunningham","year":"2022","unstructured":"Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022;136(3):197\u2013222.","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"2883_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen CDK, Yi C. YAP\/TAZ Signaling and Resistance to Cancer Therapy. Trends Cancer. 2019;5(5):283\u201396.","journal-title":"Trends Cancer"},{"issue":"6","key":"2883_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato F, Cordenonsi M, Piccolo S. YAP\/TAZ at the Roots of Cancer. Cancer Cell. 2016;29(6):783\u2013803.","journal-title":"Cancer Cell"},{"issue":"1","key":"2883_CR50","first-page":"9","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo S, et al. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023;4(1):9\u201326.","journal-title":"Nat Cancer"},{"key":"2883_CR51","doi-asserted-by":"publisher","first-page":"944494","DOI":"10.3389\/fonc.2022.944494","volume":"12","author":"J Deng","year":"2022","unstructured":"Deng J, et al. CXCL5: A coachman to drive cancer progression. Front Oncol. 2022;12:944494.","journal-title":"Front Oncol"},{"issue":"1","key":"2883_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang G, et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016;6(1):80\u201395.","journal-title":"Cancer Discov"},{"issue":"1","key":"2883_CR53","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, et al. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7(1):376.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2883_CR54","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tcb.2023.08.003","volume":"34","author":"H Su","year":"2024","unstructured":"Su H, Karin M. Multifaceted collagen-DDR1 signaling in cancer. Trends Cell Biol. 2024;34(5):406\u201315.","journal-title":"Trends Cell Biol"},{"key":"2883_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono T, et al. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2.","journal-title":"Inflamm Regen"},{"key":"2883_CR56","doi-asserted-by":"publisher","first-page":"1063815","DOI":"10.3389\/fendo.2022.1063815","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. The RANK\/RANKL\/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne). 2022;13:1063815.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2883_CR57","doi-asserted-by":"crossref","unstructured":"N\u00f8rregaard KS et al. Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity. Int J Mol Sci. 2021;22(13):6865.","DOI":"10.3390\/ijms22136865"},{"issue":"4","key":"2883_CR58","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12178-015-9310-y","volume":"8","author":"GM Cote","year":"2015","unstructured":"Cote GM. Rank ligand as a target in musculoskeletal neoplasms. Curr Rev Musculoskelet Med. 2015;8(4):339\u201343.","journal-title":"Curr Rev Musculoskelet Med"},{"key":"2883_CR59","doi-asserted-by":"crossref","unstructured":"Pilard C et al. RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. J Immunother Cancer. 2025;13(3):e010753.","DOI":"10.1136\/jitc-2024-010753"},{"key":"2883_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","volume":"5","author":"MC Walsh","year":"2014","unstructured":"Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol. 2014;5:511.","journal-title":"Front Immunol"},{"issue":"7","key":"2883_CR61","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1172\/JCI13890","volume":"108","author":"J Lam","year":"2001","unstructured":"Lam J, et al. Crystal structure of the TRANCE\/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001;108(7):971\u20139.","journal-title":"J Clin Invest"},{"issue":"5706","key":"2883_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"key":"2883_CR63","doi-asserted-by":"publisher","first-page":"719836","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, et al. Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol. 2021;11:719836.","journal-title":"Front Oncol"},{"issue":"11","key":"2883_CR64","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55(11):2308\u201319.","journal-title":"Exp Mol Med"},{"issue":"3","key":"2883_CR65","doi-asserted-by":"publisher","first-page":"e90518","DOI":"10.1371\/journal.pone.0090518","volume":"9","author":"M Guo","year":"2014","unstructured":"Guo M, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1\u03b1 activation in human osteosarcoma. PLoS ONE. 2014;9(3):e90518.","journal-title":"PLoS ONE"},{"key":"2883_CR66","doi-asserted-by":"publisher","first-page":"1350187","DOI":"10.3389\/fphar.2024.1350187","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, et al. Hypoxia inducible factor-1\u0251 as a potential therapeutic target for osteosarcoma metastasis. Front Pharmacol. 2024;15:1350187.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2883_CR67","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.21873\/anticanres.15293","volume":"41","author":"SY Yang","year":"2021","unstructured":"Yang SY, et al. Effects of Hypoxia on Proliferation and Apoptosis of Osteosarcoma Cells. Anticancer Res. 2021;41(10):4781\u20137.","journal-title":"Anticancer Res"},{"issue":"6","key":"2883_CR68","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315.","journal-title":"Nat Med"},{"issue":"9","key":"2883_CR69","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","volume":"14","author":"J Fang","year":"2023","unstructured":"Fang J, et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023;14(9):586.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2883_CR70","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439\u201353.","journal-title":"J Exp Med"},{"issue":"2","key":"2883_CR71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"EK Jo","year":"2016","unstructured":"Jo EK, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13(2):148\u201359.","journal-title":"Cell Mol Immunol"},{"key":"2883_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.yjmcc.2017.12.007","volume":"115","author":"Y Dautova","year":"2018","unstructured":"Dautova Y, et al. Calcium phosphate particles stimulate interleukin-1\u03b2 release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release. J Mol Cell Cardiol. 2018;115:82\u201393.","journal-title":"J Mol Cell Cardiol"},{"key":"2883_CR73","doi-asserted-by":"crossref","unstructured":"Murakami T et al. Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases. Int J Mol Sci. 2022;23(10):5365.","DOI":"10.3390\/ijms23105365"},{"issue":"7","key":"2883_CR74","doi-asserted-by":"publisher","first-page":"602","DOI":"10.4049\/immunohorizons.2100066","volume":"5","author":"F Anzai","year":"2021","unstructured":"Anzai F, et al. Calciprotein Particles Induce IL-1\u03b2\/\u03b1-Mediated Inflammation through NLRP3 Inflammasome-Dependent and -Independent Mechanisms. Immunohorizons. 2021;5(7):602\u201314.","journal-title":"Immunohorizons"},{"issue":"7578","key":"2883_CR75","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329\u201335.","journal-title":"Nature"},{"issue":"1","key":"2883_CR76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","volume":"18","author":"Y Guo","year":"2019","unstructured":"Guo Y, et al. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019;18(1):39.","journal-title":"Mol Cancer"},{"issue":"1","key":"2883_CR77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41392-020-00414-1","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021;6(1):59.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2883_CR78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41392-020-00273-w","volume":"5","author":"K Xie","year":"2020","unstructured":"Xie K, Zhang X, Tao Y. Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis. Signal Transduct Target Ther. 2020;5(1):161.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2883_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41423-025-01323-5","volume":"22","author":"W Wang","year":"2025","unstructured":"Wang W, et al. The role of exosomes in immunopathology and potential therapeutic implications. Cell Mol Immunol. 2025;22(9):975\u201395.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2883_CR80","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12935-024-03488-x","volume":"24","author":"P Wang","year":"2024","unstructured":"Wang P, et al. The sEVs miR-487a\/Notch2\/GATA3 axis promotes osteosarcoma lung metastasis by inducing macrophage polarization toward the M2-subtype. Cancer Cell Int. 2024;24(1):301.","journal-title":"Cancer Cell Int"},{"issue":"8","key":"2883_CR81","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186(8):1580\u2013609.","journal-title":"Cell"},{"key":"2883_CR82","doi-asserted-by":"crossref","unstructured":"Schmidt AA et al. Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression. Cancers (Basel). 2025;17(19):3106.","DOI":"10.3390\/cancers17193106"},{"key":"2883_CR83","first-page":"391967","volume":"2014","author":"SP D\u2019Angelo","year":"2014","unstructured":"D\u2019Angelo SP, et al. Sarcoma immunotherapy: past approaches and future directions. Sarcoma. 2014;2014:391967.","journal-title":"Sarcoma"},{"key":"2883_CR84","doi-asserted-by":"publisher","first-page":"30093","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala P, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6:30093.","journal-title":"Sci Rep"},{"issue":"11","key":"2883_CR85","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00262-024-03822-2","volume":"73","author":"SL Renne","year":"2024","unstructured":"Renne SL, et al. Disruptions in antigen processing and presentation machinery on sarcoma. Cancer Immunol Immunother. 2024;73(11):228.","journal-title":"Cancer Immunol Immunother"},{"key":"2883_CR86","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2016.00353","volume":"7","author":"Z Wang","year":"2016","unstructured":"Wang Z, et al. T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol. 2016;7:353.","journal-title":"Front Immunol"},{"key":"2883_CR87","doi-asserted-by":"crossref","unstructured":"Ligon JA et al. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. J Immunother Cancer. 2021;9(5):e001772.","DOI":"10.1136\/jitc-2020-001772"},{"key":"2883_CR88","doi-asserted-by":"publisher","first-page":"1539696","DOI":"10.3389\/fimmu.2024.1539696","volume":"15","author":"C Luo","year":"2024","unstructured":"Luo C, Min X, Zhang D. New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma. Front Immunol. 2024;15:1539696.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR89","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2883_CR90","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"key":"2883_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","volume":"23","author":"CH Ries","year":"2015","unstructured":"Ries CH, et al. CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. 2015;23:45\u201351.","journal-title":"Curr Opin Pharmacol"},{"key":"2883_CR92","doi-asserted-by":"crossref","unstructured":"Tomassetti C et al. Insights into CSF-1R Expression in the Tumor Microenvironment. Biomedicines. 2024;12(10):2381.","DOI":"10.3390\/biomedicines12102381"},{"key":"2883_CR93","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","volume":"76","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Targeting macrophages in cancer immunotherapy: Frontiers and challenges. J Adv Res. 2025;76:695\u2013713.","journal-title":"J Adv Res"},{"issue":"7355","key":"2883_CR94","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"},{"issue":"21","key":"2883_CR95","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJ Waugh","year":"2008","unstructured":"Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735\u201341.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2883_CR96","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41423-020-00613-4","volume":"18","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, et al. Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell Mol Immunol. 2021;18(3):566\u201378.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2883_CR97","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2007","unstructured":"Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568\u201373.","journal-title":"Blood"},{"issue":"8","key":"2883_CR98","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641\u201354.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2883_CR99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, et al. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344.","journal-title":"Immunol Rev"},{"key":"2883_CR100","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","volume":"5","author":"A Ohta","year":"2014","unstructured":"Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014;5:304.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2883_CR102","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2883_CR103","first-page":"547","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T Cell Dysfunct Cancer Cancer Cell. 2018;33(4):547\u201362.","journal-title":"T Cell Dysfunct Cancer Cancer Cell"},{"issue":"1","key":"2883_CR104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2883_CR105","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","volume":"7","author":"L Maggs","year":"2021","unstructured":"Maggs L, et al. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends Cancer. 2021;7(12):1089\u2013101.","journal-title":"Trends Cancer"},{"issue":"1","key":"2883_CR106","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194.","journal-title":"Mol Cancer"},{"issue":"9","key":"2883_CR107","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"2883_CR108","doi-asserted-by":"publisher","first-page":"e0284645","DOI":"10.1371\/journal.pone.0284645","volume":"18","author":"SS Withers","year":"2023","unstructured":"Withers SS, et al. Effect of stimulator of interferon genes (STING) signaling on radiation-induced chemokine expression in human osteosarcoma cells. PLoS ONE. 2023;18(4):e0284645.","journal-title":"PLoS ONE"},{"issue":"3","key":"2883_CR109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79(3):191.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2883_CR110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12967-023-03961-7","volume":"21","author":"Y Sun","year":"2023","unstructured":"Sun Y, et al. Abnormal signal pathways and tumor heterogeneity in osteosarcoma. J Transl Med. 2023;21(1):99.","journal-title":"J Transl Med"},{"issue":"1","key":"2883_CR111","doi-asserted-by":"publisher","first-page":"e23601","DOI":"10.1016\/j.heliyon.2023.e23601","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Single-cell RNA sequencing reveals the immune microenvironment landscape of osteosarcoma before and after chemotherapy. Heliyon. 2024;10(1):e23601.","journal-title":"Heliyon"},{"issue":"1","key":"2883_CR112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-024-01598-7","volume":"17","author":"X Zheng","year":"2024","unstructured":"Zheng X, et al. A single-cell and spatially resolved atlas of human osteosarcomas. J Hematol Oncol. 2024;17(1):71.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2883_CR113","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12885-025-13714-y","volume":"25","author":"F Liu","year":"2025","unstructured":"Liu F, et al. Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis. BMC Cancer. 2025;25(1):280.","journal-title":"BMC Cancer"},{"issue":"15","key":"2883_CR114","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-24-0563","volume":"30","author":"DD Truong","year":"2024","unstructured":"Truong DD, et al. Mapping the Single-Cell Differentiation Landscape of Osteosarcoma. Clin Cancer Res. 2024;30(15):3259\u201372.","journal-title":"Clin Cancer Res"},{"key":"2883_CR115","doi-asserted-by":"publisher","first-page":"1640645","DOI":"10.3389\/fonc.2025.1640645","volume":"15","author":"G Qiu","year":"2025","unstructured":"Qiu G, et al. Deciphering spatially confined immune evasion niches in osteosarcoma with 3-D spatial transcriptomics: a literature review. Front Oncol. 2025;15:1640645.","journal-title":"Front Oncol"},{"issue":"1","key":"2883_CR116","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11(1):6322.","journal-title":"Nat Commun"},{"issue":"1","key":"2883_CR117","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41413-022-00237-6","volume":"11","author":"W Liu","year":"2023","unstructured":"Liu W, et al. Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma. Bone Res. 2023;11(1):4.","journal-title":"Bone Res"},{"issue":"1","key":"2883_CR118","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-023-02886-9","volume":"42","author":"SFF Almeida","year":"2023","unstructured":"Almeida SFF, et al. Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodelling. J Exp Clin Cancer Res. 2023;42(1):328.","journal-title":"J Exp Clin Cancer Res"},{"key":"2883_CR119","doi-asserted-by":"publisher","first-page":"780264","DOI":"10.3389\/fonc.2021.780264","volume":"11","author":"G Sheng","year":"2021","unstructured":"Sheng G, et al. Osteosarcoma and Metastasis. Front Oncol. 2021;11:780264.","journal-title":"Front Oncol"},{"key":"2883_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fonc.2020.00013","volume":"10","author":"TM Fan","year":"2020","unstructured":"Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020;10:13.","journal-title":"Front Oncol"},{"issue":"1","key":"2883_CR121","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2883_CR122","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ccell.2023.02.018","volume":"41","author":"L Patras","year":"2023","unstructured":"Patras L, et al. Immune determinants of the pre-metastatic niche. Cancer Cell. 2023;41(3):546\u201372.","journal-title":"Cancer Cell"},{"issue":"5","key":"2883_CR123","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"},{"issue":"5","key":"2883_CR124","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302\u201317.","journal-title":"Nat Rev Cancer"},{"key":"2883_CR125","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2020.06.037","volume":"325","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Han M, Gao J. Prognosis and targeting of pre-metastatic niche. J Control Release. 2020;325:223\u201334.","journal-title":"J Control Release"},{"issue":"7069","key":"2883_CR126","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u20137.","journal-title":"Nature"},{"key":"2883_CR127","doi-asserted-by":"publisher","first-page":"703640","DOI":"10.3389\/fmolb.2021.703640","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, et al. The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors. Front Mol Biosci. 2021;8:703640.","journal-title":"Front Mol Biosci"},{"key":"2883_CR128","doi-asserted-by":"crossref","unstructured":"Cheng J et al. Non-Coding RNAs Derived from Extracellular Vesicles Promote Pre-Metastatic Niche Formation and Tumor Distant Metastasis. Cancers (Basel). 2023;15(7):2158.","DOI":"10.3390\/cancers15072158"},{"key":"2883_CR129","doi-asserted-by":"publisher","first-page":"737314","DOI":"10.3389\/fcell.2021.737314","volume":"9","author":"L Yang","year":"2021","unstructured":"Yang L, et al. Exosomes as Efficient Nanocarriers in Osteosarcoma: Biological Functions and Potential Clinical Applications. Front Cell Dev Biol. 2021;9:737314.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2883_CR130","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/prd.12561","volume":"94","author":"RJ Miron","year":"2024","unstructured":"Miron RJ, et al. Understanding exosomes: Part 2-Emerging leaders in regenerative medicine. Periodontol 2000. 2024;94(1):257\u2013414.","journal-title":"Periodontol 2000"},{"key":"2883_CR131","doi-asserted-by":"crossref","unstructured":"Chic\u00f3n-Bosch M, Tirado OM. Exosomes in Bone Sarcomas: Key Players in Metastasis. Cells. 2020;9(1):241.","DOI":"10.3390\/cells9010241"},{"key":"2883_CR132","doi-asserted-by":"crossref","unstructured":"Mazumdar A et al. Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming. Int J Mol Sci. 2020;21(15):5451.","DOI":"10.3390\/ijms21155451"},{"issue":"1","key":"2883_CR133","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-019-1101-4","volume":"18","author":"J Kong","year":"2019","unstructured":"Kong J, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019;18(1):175.","journal-title":"Mol Cancer"},{"key":"2883_CR134","doi-asserted-by":"publisher","first-page":"117203","DOI":"10.1016\/j.biopha.2024.117203","volume":"178","author":"X Zhongyu","year":"2024","unstructured":"Zhongyu X, et al. Review of pre-metastatic niches induced by osteosarcoma-derived extracellular vesicles in lung metastasis: A potential opportunity for diagnosis and intervention. Biomed Pharmacother. 2024;178:117203.","journal-title":"Biomed Pharmacother"},{"key":"2883_CR135","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.gene.2019.06.005","volume":"710","author":"S Jerez","year":"2019","unstructured":"Jerez S, et al. Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis. Gene. 2019;710:246\u201357.","journal-title":"Gene"},{"key":"2883_CR136","doi-asserted-by":"publisher","first-page":"902049","DOI":"10.3389\/fphar.2022.902049","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, et al. Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions. Front Pharmacol. 2022;13:902049.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2883_CR137","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/carcin\/bgz130","volume":"41","author":"L Raimondi","year":"2020","unstructured":"Raimondi L, et al. Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs. Carcinogenesis. 2020;41(5):666\u201377.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2883_CR138","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12935-023-03121-3","volume":"23","author":"X Chang","year":"2023","unstructured":"Chang X, et al. Tumor-derived exosomal linc00881 induces lung fibroblast activation and promotes osteosarcoma lung migration. Cancer Cell Int. 2023;23(1):287.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2883_CR139","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/1541-7786.MCR-16-0163","volume":"15","author":"S Maji","year":"2017","unstructured":"Maji S, et al. Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis. Mol Cancer Res. 2017;15(1):93\u2013105.","journal-title":"Mol Cancer Res"},{"issue":"19","key":"2883_CR140","doi-asserted-by":"publisher","first-page":"28697","DOI":"10.18632\/oncotarget.7376","volume":"7","author":"SY Lim","year":"2016","unstructured":"Lim SY, et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697\u2013710.","journal-title":"Oncotarget"},{"issue":"8","key":"2883_CR141","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/cas.13653","volume":"109","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, et al. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613. Cancer Sci. 2018;109(8):2412\u201322.","journal-title":"Cancer Sci"},{"key":"2883_CR142","doi-asserted-by":"crossref","unstructured":"Albrengues J et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409):eaao4227.","DOI":"10.1126\/science.aao4227"},{"issue":"2","key":"2883_CR143","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12016-020-08804-7","volume":"61","author":"V Mutua","year":"2021","unstructured":"Mutua V, Gershwin LJ. A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. Clin Rev Allergy Immunol. 2021;61(2):194\u2013211.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2883_CR144","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3389\/fimmu.2020.01749","volume":"11","author":"MT Masucci","year":"2020","unstructured":"Masucci MT, et al. The Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis. Front Immunol. 2020;11:1749.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-024-01933-x","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024;9(1):235.","journal-title":"Signal Transduct Target Ther"},{"key":"2883_CR146","doi-asserted-by":"crossref","unstructured":"Ma Y et al. Neutrophil extracellular traps in cancer. MedComm (2020), 2024. 5(8): p. e647.","DOI":"10.1002\/mco2.647"},{"key":"2883_CR147","doi-asserted-by":"crossref","unstructured":"Rayes RF et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects. JCI Insight. 2019;5(16):e128008.","DOI":"10.1172\/jci.insight.128008"},{"key":"2883_CR148","doi-asserted-by":"crossref","unstructured":"Wang D et al. The lung pre-metastatic niche in osteosarcoma: Mechanism and therapeutic intervention. Int J Cancer, 2025. Online ahead of print.","DOI":"10.1002\/ijc.70188"},{"issue":"4","key":"2883_CR149","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10585-017-9870-x","volume":"35","author":"GS Karagiannis","year":"2018","unstructured":"Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metastasis. 2018;35(4):269\u201384.","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"2883_CR150","doi-asserted-by":"publisher","first-page":"102143","DOI":"10.1016\/j.labinv.2024.102143","volume":"104","author":"C Yang","year":"2024","unstructured":"Yang C, et al. Spatial Heterogeneity of PD-1\/PD-L1 Defined Osteosarcoma Microenvironments at Single-Cell Spatial Resolution. Lab Invest. 2024;104(11):102143.","journal-title":"Lab Invest"},{"issue":"1","key":"2883_CR151","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540.","journal-title":"Nat Commun"},{"issue":"10","key":"2883_CR152","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"2883_CR153","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10561-020-09831-6","volume":"21","author":"S Zang","year":"2020","unstructured":"Zang S, et al. Establishment of a dynamic osteosarcoma biobank: Ruijin experience. Cell Tissue Bank. 2020;21(3):447\u201355.","journal-title":"Cell Tissue Bank"},{"key":"2883_CR154","doi-asserted-by":"crossref","unstructured":"Liang J et al. Multi-modal optimization to identify personalized biomarkers for disease prediction of individual patients with cancer. Brief Bioinform. 2022;23(5):bbac254.","DOI":"10.1093\/bib\/bbac254"},{"issue":"8066","key":"2883_CR155","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-025-08878-3","volume":"642","author":"LV Schaffer","year":"2025","unstructured":"Schaffer LV, et al. Multimodal cell maps as a foundation for structural and functional genomics. Nature. 2025;642(8066):222\u201331.","journal-title":"Nature"},{"key":"2883_CR156","unstructured":"Biermann JS et al. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(4):e250017."},{"issue":"12","key":"2883_CR157","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2883_CR158","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/annonc\/mdx034","volume":"28","author":"EJ Limkin","year":"2017","unstructured":"Limkin EJ, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 2017;28(6):1191\u2013206.","journal-title":"Ann Oncol"},{"issue":"10","key":"2883_CR159","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s11547-021-01389-x","volume":"126","author":"C Scapicchio","year":"2021","unstructured":"Scapicchio C, et al. A deep look into radiomics. Radiol Med. 2021;126(10):1296\u2013311.","journal-title":"Radiol Med"},{"key":"2883_CR160","doi-asserted-by":"crossref","unstructured":"Verma V et al. The Rise of Radiomics and Implications for Oncologic Management. J Natl Cancer Inst. 2017;109(7):djx055.","DOI":"10.1093\/jnci\/djx055"},{"issue":"12","key":"2883_CR161","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1016\/j.acra.2024.07.015","volume":"31","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Magnetic Resonance Imaging Radiomics Predicts Histological Response to Neoadjuvant Chemotherapy in Localized High-grade Osteosarcoma of the Extremities. Acad Radiol. 2024;31(12):5100\u20137.","journal-title":"Acad Radiol"},{"issue":"1","key":"2883_CR162","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1038\/s41467-020-17678-4","volume":"11","author":"B Schmauch","year":"2020","unstructured":"Schmauch B, et al. A deep learning model to predict RNA-Seq expression of tumours from whole slide images. Nat Commun. 2020;11(1):3877.","journal-title":"Nat Commun"},{"issue":"1","key":"2883_CR163","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41467-025-57072-6","volume":"16","author":"P Zhang","year":"2025","unstructured":"Zhang P, et al. Systematic inference of super-resolution cell spatial profiles from histology images. Nat Commun. 2025;16(1):1838.","journal-title":"Nat Commun"},{"issue":"1","key":"2883_CR164","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-025-01502-z","volume":"17","author":"HM Hieromnimon","year":"2025","unstructured":"Hieromnimon HM, et al. Building digital histology models of transcriptional tumor programs with generative deep learning for pathology-based precision medicine. Genome Med. 2025;17(1):87.","journal-title":"Genome Med"},{"key":"2883_CR165","doi-asserted-by":"crossref","unstructured":"Wu Y et al. DANet: spatial gene expression prediction from H&E histology images through dynamic alignment. Brief Bioinform. 2025;26(4):bbaf422.","DOI":"10.1093\/bib\/bbaf422"},{"key":"2883_CR166","doi-asserted-by":"crossref","unstructured":"Wang Y et al. FmH2ST: foundation model-based spatial transcriptomics generation from histological images. Nucleic Acids Res. 2025;53(17):gkaf865.","DOI":"10.1093\/nar\/gkaf865"},{"issue":"10","key":"2883_CR167","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41422-020-0370-1","volume":"30","author":"K Matsuoka","year":"2020","unstructured":"Matsuoka K, et al. Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020;30(10):885\u2013901.","journal-title":"Cell Res"},{"key":"2883_CR168","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.eclinm.2024.102697","volume":"73","author":"Y Fu","year":"2024","unstructured":"Fu Y, et al. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. EClinicalMedicine. 2024;73:102697.","journal-title":"EClinicalMedicine"},{"key":"2883_CR169","doi-asserted-by":"crossref","unstructured":"Maqueda JJ, De Feo A, Scotlandi K. Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions. Biomolecules. 2024;14(10):1306.","DOI":"10.3390\/biom14101306"},{"issue":"7","key":"2883_CR170","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41571-019-0202-8","volume":"16","author":"D Killock","year":"2019","unstructured":"Killock D. bTMB is a promising predictive biomarker. Nat Rev Clin Oncol. 2019;16(7):403.","journal-title":"Nat Rev Clin Oncol"},{"key":"2883_CR171","doi-asserted-by":"publisher","first-page":"1172108","DOI":"10.3389\/fgene.2023.1172108","volume":"14","author":"L Zhu","year":"2023","unstructured":"Zhu L, et al. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review. Front Genet. 2023;14:1172108.","journal-title":"Front Genet"},{"issue":"6","key":"2883_CR172","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.annonc.2023.12.006","volume":"35","author":"B Audinot","year":"2024","unstructured":"Audinot B, et al. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. Ann Oncol. 2024;35(6):559\u201368.","journal-title":"Ann Oncol"},{"key":"2883_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.03.002","volume":"168","author":"I Lyskj\u00e6r","year":"2022","unstructured":"Lyskj\u00e6r I, et al. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. Eur J Cancer. 2022;168:1\u201311.","journal-title":"Eur J Cancer"},{"issue":"18","key":"2883_CR174","doi-asserted-by":"publisher","first-page":"7669","DOI":"10.1002\/cam4.2632","volume":"8","author":"L Li","year":"2019","unstructured":"Li L, et al. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. Cancer Med. 2019;8(18):7669\u201378.","journal-title":"Cancer Med"},{"issue":"D1","key":"2883_CR175","doi-asserted-by":"publisher","first-page":"D468","DOI":"10.1093\/nar\/gkaa796","volume":"49","author":"SY Chen","year":"2021","unstructured":"Chen SY, et al. TCRdb: a comprehensive database for T-cell receptor sequences with powerful search function. Nucleic Acids Res. 2021;49(D1):D468\u201374.","journal-title":"Nucleic Acids Res"},{"key":"2883_CR176","doi-asserted-by":"publisher","first-page":"954078","DOI":"10.3389\/fimmu.2022.954078","volume":"13","author":"K Peng","year":"2022","unstructured":"Peng K, et al. pyTCR: A comprehensive and scalable solution for TCR-Seq data analysis to facilitate reproducibility and rigor of immunogenomics research. Front Immunol. 2022;13:954078.","journal-title":"Front Immunol"},{"issue":"2","key":"2883_CR177","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btab661","volume":"38","author":"C Wong","year":"2022","unstructured":"Wong C, Li B. AutoCAT: automated cancer-associated TCRs discovery from TCR-seq data. Bioinformatics. 2022;38(2):589\u201391.","journal-title":"Bioinformatics"},{"issue":"10","key":"2883_CR178","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.immuni.2022.09.002","volume":"55","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022;55(10):1940. \u20131952.e5.","journal-title":"Immunity"},{"key":"2883_CR179","doi-asserted-by":"publisher","first-page":"587014","DOI":"10.3389\/fimmu.2020.587014","volume":"11","author":"J Kidman","year":"2020","unstructured":"Kidman J, et al. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Front Immunol. 2020;11:587014.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR180","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","volume":"41","author":"N Porciello","year":"2022","unstructured":"Porciello N, et al. T-cell repertoire diversity: friend or foe for protective antitumor response? J Exp Clin Cancer Res. 2022;41(1):356.","journal-title":"J Exp Clin Cancer Res"},{"key":"2883_CR181","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fimmu.2019.01336","volume":"10","author":"A Arakawa","year":"2019","unstructured":"Arakawa A, et al. Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. Front Immunol. 2019;10:1336.","journal-title":"Front Immunol"},{"issue":"3","key":"2883_CR182","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3892\/ol.2021.12473","volume":"21","author":"Y Kim","year":"2021","unstructured":"Kim Y, et al. Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. Oncol Lett. 2021;21(3):212.","journal-title":"Oncol Lett"},{"key":"2883_CR183","doi-asserted-by":"crossref","unstructured":"Cascini C, Chiodoni C. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells. 2021;10(7):1668.","DOI":"10.3390\/cells10071668"},{"issue":"9","key":"2883_CR184","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","volume":"70","author":"K Boye","year":"2021","unstructured":"Boye K, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021;70(9):2617\u201324.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2883_CR185","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2883_CR186","doi-asserted-by":"publisher","first-page":"117194","DOI":"10.1016\/j.bcp.2025.117194","volume":"241","author":"X Kong","year":"2025","unstructured":"Kong X, et al. Transforming the cold tumors to hot tumors: strategies for immune activation. Biochem Pharmacol. 2025;241:117194.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2883_CR187","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu YT, et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer. 2025;24(1):254.","journal-title":"Mol Cancer"},{"issue":"1","key":"2883_CR188","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"key":"2883_CR189","doi-asserted-by":"crossref","unstructured":"Galluzzi L et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"2883_CR190","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"2883_CR191","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, et al. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"2883_CR192","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Adv Sci (Weinh). 2022;9(22):e2201734.","journal-title":"Adv Sci (Weinh)"},{"key":"2883_CR193","doi-asserted-by":"crossref","unstructured":"Janopaul-Naylor JR et al. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. Int J Mol Sci. 2021;22(20):11061.","DOI":"10.3390\/ijms222011061"},{"key":"2883_CR194","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"1","key":"2883_CR195","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2883_CR196","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2883_CR197","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1878-0261.12658","volume":"14","author":"M Mondini","year":"2020","unstructured":"Mondini M, et al. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol. 2020;14(7):1529\u201337.","journal-title":"Mol Oncol"},{"issue":"1","key":"2883_CR198","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361.","journal-title":"Nat Med"},{"issue":"7","key":"2883_CR199","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"5","key":"2883_CR200","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605\u201322.","journal-title":"Cancer Cell"},{"issue":"3","key":"2883_CR201","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122(3):899\u2013910.","journal-title":"J Clin Invest"},{"issue":"23","key":"2883_CR202","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1007\/s00018-013-1339-8","volume":"70","author":"E Peranzoni","year":"2013","unstructured":"Peranzoni E, et al. Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci. 2013;70(23):4431\u201348.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2883_CR203","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/cas.13169","volume":"108","author":"M Matsuki","year":"2017","unstructured":"Matsuki M, et al. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Sci. 2017;108(4):763\u201371.","journal-title":"Cancer Sci"},{"issue":"1","key":"2883_CR204","doi-asserted-by":"publisher","first-page":"107327481878936","DOI":"10.1177\/1073274818789361","volume":"25","author":"K Suyama","year":"2018","unstructured":"Suyama K, Iwase H. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018;25(1):1073274818789361.","journal-title":"Cancer Control"},{"key":"2883_CR205","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fonc.2014.00070","volume":"4","author":"T Voron","year":"2014","unstructured":"Voron T, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.","journal-title":"Front Oncol"},{"issue":"2","key":"2883_CR206","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8\u2009+\u2009T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14(2):e0212513.","journal-title":"PLoS ONE"},{"key":"2883_CR207","doi-asserted-by":"crossref","unstructured":"Xie L et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020;8(1):e000798.","DOI":"10.1136\/jitc-2020-000798"},{"key":"2883_CR208","doi-asserted-by":"crossref","unstructured":"Correction. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020;8(1):e000798corr1.","DOI":"10.1136\/jitc-2020-000798corr1"},{"issue":"2","key":"2883_CR209","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/0008-5472.CAN-15-2621","volume":"77","author":"C Reynaud","year":"2017","unstructured":"Reynaud C, et al. Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. Cancer Res. 2017;77(2):268\u201378.","journal-title":"Cancer Res"},{"issue":"12","key":"2883_CR210","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1021\/acs.jmedchem.9b00335","volume":"62","author":"L Leung","year":"2019","unstructured":"Leung L, et al. Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships. J Med Chem. 2019;62(12):5863\u201384.","journal-title":"J Med Chem"},{"issue":"8","key":"2883_CR211","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949\u201356.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2883_CR212","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med"},{"issue":"5","key":"2883_CR213","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651\u201362.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2883_CR214","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-16-2748","volume":"23","author":"AF Schott","year":"2017","unstructured":"Schott AF, et al. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2017;23(18):5358\u201365.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2883_CR215","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17\u201335.","journal-title":"Immunity"},{"issue":"1","key":"2883_CR216","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020;10(1):40\u201353.","journal-title":"Cancer Discov"},{"key":"2883_CR217","doi-asserted-by":"crossref","unstructured":"Melisi D et al. Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021;9(3):e002068.","DOI":"10.1136\/jitc-2020-002068"},{"key":"2883_CR218","doi-asserted-by":"publisher","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"ZH Wang","year":"2021","unstructured":"Wang ZH, et al. Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMedicine. 2021;73:103627.","journal-title":"EBioMedicine"},{"issue":"1","key":"2883_CR219","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","volume":"122","author":"CA Opitz","year":"2020","unstructured":"Opitz CA, et al. The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer. 2020;122(1):30\u201344.","journal-title":"Br J Cancer"},{"issue":"12","key":"2883_CR220","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, et al. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015;3(12):1375\u201385.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2883_CR221","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00018-011-0659-9","volume":"68","author":"G Mester","year":"2011","unstructured":"Mester G, Hoffmann V, Stevanovi\u0107 S. Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci. 2011;68(9):1521\u201332.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2883_CR222","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, et al. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2883_CR223","doi-asserted-by":"publisher","first-page":"e70140","DOI":"10.1002\/ctm2.70140","volume":"15","author":"PY Lam","year":"2025","unstructured":"Lam PY, et al. Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clin Transl Med. 2025;15(1):e70140.","journal-title":"Clin Transl Med"},{"key":"2883_CR224","doi-asserted-by":"crossref","unstructured":"Quamine AE et al. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. Cancers (Basel). 2021;13(11):2796.","DOI":"10.3390\/cancers13112796"},{"issue":"10","key":"2883_CR225","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"3","key":"2883_CR226","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/1535-7163.MCT-20-0406","volume":"20","author":"P Hingorani","year":"2021","unstructured":"Hingorani P, et al. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther. 2021;20(3):535\u201340.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"2883_CR227","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3556\u201366.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2883_CR228","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"2883_CR229","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","volume":"30","author":"LJ Talbot","year":"2024","unstructured":"Talbot LJ, et al. Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clin Cancer Res. 2024;30(19):4434\u201349.","journal-title":"Clin Cancer Res"},{"key":"2883_CR230","doi-asserted-by":"crossref","unstructured":"Lake JA et al. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. J Immunother Cancer. 2024;12(7):e009221.","DOI":"10.1136\/jitc-2024-009221"},{"key":"2883_CR231","doi-asserted-by":"publisher","first-page":"1391954","DOI":"10.3389\/fimmu.2024.1391954","volume":"15","author":"SJ Holzmayer","year":"2024","unstructured":"Holzmayer SJ, et al. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. Front Immunol. 2024;15:1391954.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR232","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","volume":"13","author":"JA Park","year":"2020","unstructured":"Park JA, Cheung NV. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol. 2020;13(1):172.","journal-title":"J Hematol Oncol"},{"key":"2883_CR233","doi-asserted-by":"crossref","unstructured":"Yankelevich M et al. Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells. J Immunother Cancer. 2024;12(3):e008744.","DOI":"10.1136\/jitc-2023-008744"},{"key":"2883_CR234","doi-asserted-by":"crossref","unstructured":"Kulczycka M et al. CAR T-Cell Therapy in Children with Solid Tumors. J Clin Med. 2023;12(6):2326.","DOI":"10.3390\/jcm12062326"},{"key":"2883_CR235","doi-asserted-by":"publisher","first-page":"1371345","DOI":"10.3389\/fimmu.2024.1371345","volume":"15","author":"J Philippova","year":"2024","unstructured":"Philippova J, Shevchenko J, Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol. 2024;15:1371345.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR236","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40364-025-00800-3","volume":"13","author":"J Shan","year":"2025","unstructured":"Shan J, et al. A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor. Biomark Res. 2025;13(1):87.","journal-title":"Biomark Res"},{"issue":"15","key":"2883_CR237","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.7150\/thno.113887","volume":"15","author":"Y He","year":"2025","unstructured":"He Y, et al. GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma. Theranostics. 2025;15(15):7454\u201366.","journal-title":"Theranostics"},{"key":"2883_CR238","doi-asserted-by":"publisher","first-page":"1653429","DOI":"10.3389\/fimmu.2025.1653429","volume":"16","author":"P Yu","year":"2025","unstructured":"Yu P, et al. Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis. Front Immunol. 2025;16:1653429.","journal-title":"Front Immunol"},{"issue":"5","key":"2883_CR239","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437\u201348.","journal-title":"N Engl J Med"},{"key":"2883_CR240","doi-asserted-by":"publisher","first-page":"696865","DOI":"10.3389\/fonc.2021.696865","volume":"11","author":"L Xie","year":"2021","unstructured":"Xie L, et al. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. Front Oncol. 2021;11:696865.","journal-title":"Front Oncol"},{"issue":"7","key":"2883_CR241","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.32604\/or.2025.060063","volume":"33","author":"J Lv","year":"2025","unstructured":"Lv J, et al. Plasticity of myeloid-derived suppressor cells in cancer and cancer therapy. Oncol Res. 2025;33(7):1581\u201392.","journal-title":"Oncol Res"},{"issue":"1","key":"2883_CR242","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-025-02249-2","volume":"24","author":"SY Park","year":"2025","unstructured":"Park SY, et al. Harnessing myeloid cells in cancer. Mol Cancer. 2025;24(1):69.","journal-title":"Mol Cancer"},{"key":"2883_CR243","unstructured":"Grover A, Tcyganov EN, Gabrilovich DI. Myeloid Cell Reprogramming and Immune Suppression. Annu Rev Physiol. 2025;87:399\u2013421."},{"issue":"11","key":"2883_CR244","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-25-0159","volume":"13","author":"L Blanchard","year":"2025","unstructured":"Blanchard L, Mijacika A, Osorio JC. Targeting Myeloid Cells for Cancer Immunotherapy. Cancer Immunol Res. 2025;13(11):1700\u201315.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2883_CR245","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"2883_CR246","doi-asserted-by":"publisher","first-page":"1045024","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, et al. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024.","journal-title":"Front Immunol"},{"issue":"1","key":"2883_CR247","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, et al. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res. 2018;6(1):36\u201346.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2883_CR248","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2326-6066.CIR-18-0090","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, Milone MC. Neurotoxicity Associated with a High-Affinity GD2 CAR-Response. Cancer Immunol Res. 2018;6(4):496\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2883_CR249","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/2326-6066.CIR-18-0089","volume":"6","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, et al. Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter. Cancer Immunol Res. 2018;6(4):494\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2883_CR250","doi-asserted-by":"publisher","first-page":"718","DOI":"10.7150\/ijbs.14405","volume":"12","author":"H Zhang","year":"2016","unstructured":"Zhang H, et al. New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci. 2016;12(6):718\u201329.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2883_CR251","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12885-025-14007-0","volume":"25","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, et al. Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies. BMC Cancer. 2025;25(1):619.","journal-title":"BMC Cancer"},{"issue":"1","key":"2883_CR252","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","volume":"318","author":"SM Blum","year":"2023","unstructured":"Blum SM, Rouhani SJ, Sullivan RJ. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev. 2023;318(1):167\u201378.","journal-title":"Immunol Rev"},{"key":"2883_CR253","doi-asserted-by":"publisher","first-page":"804597","DOI":"10.3389\/fimmu.2022.804597","volume":"13","author":"R Poto","year":"2022","unstructured":"Poto R, et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022;13:804597.","journal-title":"Front Immunol"},{"key":"2883_CR254","doi-asserted-by":"crossref","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer, 2024. 12(7):e008591.","DOI":"10.1136\/jitc-2023-008591"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02883-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:04:06Z","timestamp":1779253446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02883-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":254,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02883-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}